Sugi Predict

Sugi Predict / Compounds / SCHEMBL162872

SCHEMBL162872

SCHEMBL162872

CCN(c1ccccc1)[N+](=O)[O-]

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.48
▸ KMT2A Q03164 5/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ CRHBP P24387 2/20 0.48
▸ CRHR2 Q13324 2/20 0.48
▸ TLR9 Q9NR96 2/20 0.48
▸ ATM Q13315 2/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ TSHR P16473 3/20 0.45
▸ GLA P06280 1/20 0.45
▸ LMNA P02545 3/20 0.41
▸ S1PR4 O95977 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ MAPK1 P28482 3/20 0.40
▸ HSP90AA1 P07900 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL20535466 0.89 HTT (0.41) ALDH1A1KMT2AMEN1CRHBPCRHR2
SCHEMBL5880844 0.83 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1CRHBPCRHR2
SCHEMBL6282927 0.82 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1CRHBPCRHR2
SCHEMBL11124464 0.80 MAPT (0.47) ALDH1A1KMT2AMEN1CRHBPCRHR2
SCHEMBL4611261 0.79 NPC1 (0.46) ALDH1A1KMT2AMEN1CRHBPCRHR2
SCHEMBL11032368 0.78 ALDH1A1 (0.48) ALDH1A1KMT2AMEN1CRHBPCRHR2
SCHEMBL28087293 0.78 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1CRHBPCRHR2
SCHEMBL28066839 0.78 ALDH1A1 (0.40) ALDH1A1KMT2AMEN1CRHBPCRHR2
SCHEMBL11745244 0.77 CRHBP (0.50) ALDH1A1KMT2AMEN1CRHBPCRHR2
SCHEMBL9438180 0.76 ALDH1A1 (0.35) ALDH1A1KMT2AMEN1CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1058 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240350609-A1 METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) 2024-10-24 — — US claimed
EP-4450082-A1 METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF Serum Institute Of India Private Limited (IN) 2024-10-23 — — EP claimed
CN-118806889-A Method for improving adsorption of polysaccharide-protein conjugates and multivalent vaccine formulations obtained therefrom 印度血清研究所私人有限公司 2024-10-22 — — CN claimed
US-20240293524-A1 MULTIPLE FUNCTIONALIZED noMV CONJUGATES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-09-05 — — US claimed
US-20230137914-A1 nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) 2023-05-04 — — US claimed
EP-4025246-A2 IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF Serum Institute Of India Private Limited (IN) 2022-07-13 — — EP claimed
CN-114728053-A Immunogenic compositions against intestinal disease and process for preparing same 印度血清研究所私人有限公司 2022-07-08 — — CN claimed
US-20220008529-A1 MULTI-FUNCTIONALIZED noMV CONJUGATES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-01-13 — — US claimed
EP-3799883-A1 NOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF GlaxoSmithKline Biologicals S.A. (BE) 2021-04-07 — — EP claimed
WO-2021044436-A2 IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) 2021-03-11 — — WO claimed
CN-108778322-A Pseudomonas aeruginosa PCRV linked antigen vaccine 葛兰素史密丝克莱恩生物有限公司 2018-11-09 — — CN claimed
EP-3365004-A1 P. AERUGINOSA PCRV-LINKED ANTIGEN VACCINES GlaxoSmithKline Biologicals S.A. (BE) 2018-08-29 — — EP claimed
WO-2018096013-A1 nOMV-ANTIGEN CONJUGATES AND USE THEREOF GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2018-05-31 — — WO claimed
CN-104519910-B Adjuvanted formulations of streptococcus pneumoniae antigens 诺华股份有限公司 2017-05-03 — — CN claimed
WO-2017067964-A1 P. AERUGINOSA PCRV-LINKED ANTIGEN VACCINES GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2017-04-27 — — WO claimed
CN-104519910-A Adjuvanted formulations of streptococcus pneumoniae antigens NOVARTIS AG 2015-04-15 — — CN claimed
EP-2822586-A1 ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE ANTIGENS Novartis AG (CH) 2015-01-14 — — EP claimed
WO-2013131983-A1 ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE ANTIGENS NOVARTIS AG (CH) 2013-09-12 — — WO claimed
EP-2254890-A1 PROCESS FOR THE DIASTEREOISOMERIC RESOLUTION OF 5-METHYLTETRAHYDROFOLIC ACID Gnosis S.p.A. (IT) 2010-12-01 — — EP claimed
WO-2009103333-A1 PROCESS FOR THE DIASTEREOISOMERIC RESOLUTION OF 5-METHYLTETRAHYDROFOLIC ACID GNOSIS S.P.A. (IT) 2009-08-27 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137914-A1 nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF VAPB, CD14, CHMP4B ALDH1A1 4669/4885KMT2A 3023/4885MEN1 269/4885
US-20240350609-A1 METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF DDOST, CD14, STT3B ALDH1A1 4882/4885KMT2A 2081/4885MEN1 2607/4885
US-20240293524-A1 MULTIPLE FUNCTIONALIZED noMV CONJUGATES CD14, VAPB, CHMP4B ALDH1A1 4653/4885KMT2A 2301/4885MEN1 494/4885
US-20220008529-A1 MULTI-FUNCTIONALIZED noMV CONJUGATES CD14, CHMP4B, VAPB ALDH1A1 4555/4885KMT2A 2509/4885MEN1 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.